MiR-29a: a potential therapeutic target and promising biomarker in tumors

J Wang, Q Zhang, D Wang, W Yan, H Sha… - Bioscience …, 2018 - portlandpress.com
MiRNAs, small non-coding RNA molecules, were recognized to be associated with the
incidence and development of diverse neoplasms. MiRNAs were small non-coding RNAs …

New frontiers for the cytoskeletal protein LASP1

E Butt, D Raman - Frontiers in oncology, 2018 - frontiersin.org
In the recent two decades, LIM and SH3 protein 1 (LASP1) has been developed from a
simple actin-binding structural protein to a tumor biomarker and subsequently to a complex …

LASP1 Induces Epithelial‐Mesenchymal Transition in Lung Cancer through the TGF‐β1/Smad/Snail Pathway

Q Xue, H Jiang, J Wang, D Wei - Canadian Respiratory Journal, 2021 - Wiley Online Library
Background. LIM and SH3 domain protein 1 (LASP1), highly expressed in a variety of
tumors, is considered as a novel tumor metastasis biomarker. However, it is unknown which …

miR-29a-3p directly targets Smad nuclear interacting protein 1 and inhibits the migration and proliferation of cervical cancer HeLa cells

Y Chen, W Zhang, L Yan, P Zheng, J Li - PeerJ, 2020 - peerj.com
Smad nuclear interacting protein 1 (SNIP1) is a nuclear protein and involved in essential
biological processes. MicroRNAs are effective regulators of tumorigenesis and cancer …

MicroRNA-133a acts as a tumour suppressor in breast cancer through targeting LASP1 Retraction in/10.3892/or. 2022.8330

Y Sui, X Zhang, H Yang, W Wei… - Oncology …, 2018 - spandidos-publications.com
Many microRNAs (miRs) have been demonstrated to play promoting or tumor suppressive
roles in human cancers including breast cancer. However, the molecular mechanism of miR …

MicroRNA 29a therapy for CEACAM6-expressing lung adenocarcinoma

SM Son, J Yun, DW Kim, YS Jung, SB Han, YH Lee… - BMC cancer, 2023 - Springer
Abstract Background Non-coding microRNAs (miRNAs) play critical roles in tumor
progression and hold great promise as therapeutic agents for multiple cancers. MicroRNA …

Apoptosis-targeted gene therapy for non-small cell lung cancer using chitosan-poly-lactic-co-glycolic acid-based nano-delivery system and CASP8 and miRs 29A-B1 …

S Chattopadhyay, SS Sarkar, S Saproo… - … in Bioengineering and …, 2023 - frontiersin.org
Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related deaths worldwide,
with resistance to apoptosis being a major driver of therapeutic resistance and aggressive …

LINC01503/miR-342-3p facilitates malignancy in non-small-cell lung cancer cells via regulating LASP1

Q Shen, Y Sun, S Xu - Respiratory research, 2020 - Springer
Background Non-small cell lung cancer (NSCLC) is one of the major types of lung cancer,
which is a prevalent human disease all over the world. LncRNA LINC01503 is a super …

MiR‐133a acts as a tumor suppressor in lung cancer progression by regulating the LASP1 and TGF‐β/Smad3 signaling pathway

Y Shen, Y Yang, Y Li - Thoracic Cancer, 2020 - Wiley Online Library
Background MiR‐133a has been confirmed to be involved in the development of multiple
cancers including non‐small cell lung cancer (NSCLC). However, the precise molecular …

[HTML][HTML] Lasp1 promotes malignant phenotype of non-small-cell lung cancer via inducing phosphorylation of FAK-AKT pathway

X Zhang, Y Liu, C Fan, L Wang, A Li, H Zhou, L Cai… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Lasp1 (LIM and SH3 domain protein 1) promotes tumor proliferation and invasion in multiple
cancer entities including non-small cell lung cancer (NSCLC). However, the molecular …